BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Achondroplasia readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Achondroplasia\, from
  ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT02724228-10775@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:VOXZOGO (Vosoritide): Phase 2 readout est. (NCT02724228)
DESCRIPTION:VOXZOGO (Vosoritide)\, phase 2\, Achondroplasia.\nStudy: A Stud
 y to Evaluate Long-Term Safety\, Tolerability\, & Efficacy of BMN 111 in C
 hildren With Achondroplasia (ACH)\nEstimated primary completion: December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/vosoritide#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT02724228
URL:https://assetmemo.bio/drug/vosoritide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04554940-10775@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:VOXZOGO (Vosoritide): Phase 2 readout est. (NCT04554940)
DESCRIPTION:VOXZOGO (Vosoritide)\, phase 2\, Achondroplasia.\nStudy: A Clin
 ical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achond
 roplasia\nEstimated primary completion: December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/vosoritide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT04554940
URL:https://assetmemo.bio/drug/vosoritide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07297875-2324@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281215
DTEND;VALUE=DATE:20281216
SUMMARY:Lavengratinib: Phase 1/2 readout est. (NCT07297875)
DESCRIPTION:Lavengratinib\, phase 1/2\, Achondroplasia.\nStudy: A Study of 
 ABSK061 to Assess Safety\, Tolerability\, Pharmacokinetics\, and Efficacy 
 in Children With Achondroplasia\nEstimated primary completion: 15 December
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/lavengratinib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0729
 7875
URL:https://assetmemo.bio/drug/lavengratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441876-10781@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:BMN 333: Phase 2/3 readout est. (NCT07441876)
DESCRIPTION:BMN 333\, phase 2/3\, Achondroplasia.\nStudy: Study to Evaluate
  the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Ach
 ondroplasia\nEstimated primary completion: June 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/bmn-333#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07441876
URL:https://assetmemo.bio/drug/bmn-333#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424018-10775@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:VOXZOGO (Vosoritide): Phase 3 readout est. (NCT03424018)
DESCRIPTION:VOXZOGO (Vosoritide)\, phase 3\, Achondroplasia.\nStudy: An Ext
 ension Study to Evaluate the Efficacy and Safety of BMN 111 in Children Wi
 th Achondroplasia\nEstimated primary completion: June 2031. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/vosoritide#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT03424018
URL:https://assetmemo.bio/drug/vosoritide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03989947-10775@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20380531
DTEND;VALUE=DATE:20380601
SUMMARY:VOXZOGO (Vosoritide): Phase 2 readout est. (NCT03989947)
DESCRIPTION:VOXZOGO (Vosoritide)\, phase 2\, Achondroplasia.\nStudy: An Ext
 ension Study to Evaluate Safety and Efficacy of BMN 111 in Children With A
 chondroplasia\nEstimated primary completion: May 2038. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/vosoritide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03989947
URL:https://assetmemo.bio/drug/vosoritide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
